GlobeNewswire Inc.··Perspective Therapeutics, Inc.Perspective Therapeutics Advances Rare Cancer Therapy With 43% Response Rate Data
Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.
CATXclinical trialcancer treatment